Literature DB >> 16836952

Treatment of functional diarrhea.

Evan S Dellon1, Yehuda Ringel.   

Abstract

Functional diarrhea (FD), one of the functional gastrointestinal disorders, is characterized by chronic or recurrent diarrhea not explained by structural or biochemical abnormalities. The treatment of FD is intimately associated with establishing the correct diagnosis. First, FD needs to be distinguished from diarrhea-predominant irritable bowel syndrome (IBS), in which, unlike in FD, abdominal pain is a primary diagnostic criterion. Next, FD must be differentiated from the myriad organic causes of chronic diarrhea. Unlike IBS, in which a positive diagnosis can be made with an acceptable level of confidence using symptom-based criteria and minimal testing, the diagnosis of FD is still primarily a diagnosis of exclusion. Thus, the onus is on the physician to eliminate potential underlying causes, both common and uncommon, in the proper clinical setting. Once the diagnosis has been established, the clinician and patient should first focus on identifying, eliminating, and/or treating aggravating factors. These may include physiologic factors (eg, small bowel bacterial overgrowth), psychological factors (eg, stress and anxiety), and dietary factors (eg, carbohydrate malabsorption). Thereafter, appropriate treatment for functional diarrhea may be instituted. Treatment options include dietary and lifestyle modification, pharmacologic therapies, and alternative modalities. Although many of these strategies have been studied in IBS, almost none of them has been examined specifically in FD. Furthermore, given the poorly understood pathophysiologic basis of FD, these treatments primarily target a patient's symptoms and presumed altered physiology rather than underlying etiologic mechanisms. Therefore, we stress that treatment must be approached in an individualized manner and that dietary and pharmacologic therapies should be part of a comprehensive therapeutic approach in which education and reassurance form the foundation. In general, we attempt to remove dietary triggers and recommend increased fiber intake. We then add anticholinergic, antispasmodic, antimotility, and antidiarrheal agents as the first line of pharmacotherapy. Should a patient not respond to these, and for patients who have a significant degree of psychological dysfunction, central acting agents, including antidepressants and/or anxiolytics, may be beneficial. During the treatment period, we also recommend that physicians keep an open mind. If signs or symptoms that suggest an ongoing or previously unrecognized organic process develop, then a re-evaluation of the clinical picture is indicated.

Entities:  

Year:  2006        PMID: 16836952     DOI: 10.1007/s11938-006-0015-6

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  42 in total

Review 1.  AGA technical review on the evaluation and management of chronic diarrhea.

Authors:  K D Fine; L R Schiller
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

Review 2.  AGA technical review on irritable bowel syndrome.

Authors:  Douglas A Drossman; Michael Camilleri; Emeran A Mayer; William E Whitehead
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

Review 3.  Systematic review on the management of irritable bowel syndrome in North America.

Authors:  Lawrence J Brandt; David Bjorkman; M Brian Fennerty; G Richard Locke; Kevin Olden; Walter Peterson; Eamonn Quigley; Philip Schoenfeld; Marvin Schuster; Nicholas Talley
Journal:  Am J Gastroenterol       Date:  2002-11       Impact factor: 10.864

4.  Perceived food intolerance in subjects with irritable bowel syndrome-- etiology, prevalence and consequences.

Authors:  K W Monsbakken; P O Vandvik; P G Farup
Journal:  Eur J Clin Nutr       Date:  2006-05       Impact factor: 4.016

5.  Ischemic colitis during treatment with alosetron.

Authors:  D Friedel; R Thomas; R S Fisher
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

Review 6.  Management of small intestinal bacterial overgrowth.

Authors:  Gregg W Van Citters; Henry C Lin
Journal:  Curr Gastroenterol Rep       Date:  2005-08

Review 7.  Psychiatric and psychological dysfunction in irritable bowel syndrome and the role of psychological treatments.

Authors:  Olafur S Palsson; Douglas A Drossman
Journal:  Gastroenterol Clin North Am       Date:  2005-06       Impact factor: 3.806

8.  Effect of cholecystectomy on bowel function: a prospective, controlled study.

Authors:  S D Hearing; L A Thomas; K W Heaton; L Hunt
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

9.  Intestinal transit in anxiety and depression.

Authors:  D A Gorard; J E Gomborone; G W Libby; M J Farthing
Journal:  Gut       Date:  1996-10       Impact factor: 23.059

Review 10.  Pharmacologic therapy for the irritable bowel syndrome.

Authors:  Nicholas J Talley
Journal:  Am J Gastroenterol       Date:  2003-04       Impact factor: 10.864

View more
  5 in total

1.  Predictors of abdominal pain in depressed pediatric inflammatory bowel disease patients.

Authors:  Arvind I Srinath; Alka Goyal; Lori A Zimmerman; Melissa C Newara; Margaret A Kirshner; Francis Nicole McCarthy; David Keljo; David Binion; Athos Bousvaros; David R DeMaso; Ada Youk; Eva M Szigethy
Journal:  Inflamm Bowel Dis       Date:  2014-08       Impact factor: 5.325

Review 2.  Mechanisms of Electrical Activation and Conduction in the Gastrointestinal System: Lessons from Cardiac Electrophysiology.

Authors:  Gary Tse; Eric Tsz Him Lai; Jie Ming Yeo; Vivian Tse; Sunny Hei Wong
Journal:  Front Physiol       Date:  2016-05-31       Impact factor: 4.566

3.  Acupuncture for chronic diarrhea in adults: Protocol for a systematic review.

Authors:  Zongshi Qin; Bo Li; Jiani Wu; Jinhui Tian; Shang Xie; Zhi Mao; Jing Zhou; Tae-Hun Kim; Zhishun Liu
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

Review 4.  Acupuncture for Adults with Diarrhea-Predominant Irritable Bowel Syndrome or Functional Diarrhea: A Systematic Review and Meta-Analysis.

Authors:  Jianbo Guo; Xiaoxiao Xing; Jiani Wu; Hui Zhang; Yongen Yun; Zongshi Qin; Qingyong He
Journal:  Neural Plast       Date:  2020-11-22       Impact factor: 3.599

5.  Digital Therapeutics Care Utilizing Genetic and Gut Microbiome Signals for the Management of Functional Gastrointestinal Disorders: Results From a Preliminary Retrospective Study.

Authors:  Shreyas V Kumbhare; Patricia A Francis-Lyon; Dashyanng Kachru; Tejaswini Uday; Carmel Irudayanathan; Karthik M Muthukumar; Roshni R Ricchetti; Simitha Singh-Rambiritch; Juan Ugalde; Parambir S Dulai; Daniel E Almonacid; Ranjan Sinha
Journal:  Front Microbiol       Date:  2022-03-21       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.